JPRN-UMIN000043663
Completed
N/A
The exploratory study to evaluate biomarkers in prospective multicenter observational study of atezolizumab combination therapy in patients with unresectable, advanced and recurrent non-small cell lung cancer or extensive disease small cell lung cancer (J-TAIL-2) - The biomarker exploratory study in prospective multicenter observational study of atezolizumab combination therapy in lung cancer (J-TAIL-2)
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- on-small cell lung cancer or extensive disease small cell lung cancer
- Sponsor
- CHUGAI PHARMACEUTICAL CO., LTD.
- Enrollment
- 450
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •\< non\-small cell lung cancer cohort\> (1\) Patients who are unsuitable for enrolment into the study by the investigator's judgment. \<extensive disease small cell lung cancer cohort\> (1\) Patients who are unsuitable for enrolment into the study by the investigator's judgment.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Exploratory study to investigate biomarkers associated with pathogenesis of infantile hemangioma.Infantile hemangiomaJPRN-UMIN000038574Wakayama Medical University45
Not Yet Recruiting
N/A
Exploratory research of biomarkers for investigational drugs using tear fluid samplesJPRN-UMIN000049186Santen Pharmaceutical Co. Ltd.29
Recruiting
N/A
An exploratory prospective study of the biomarkers of the immune-related adverse events (irAE) and the mechanisms of irAE in solid cancer patients treated with Pembrolizumab.solid cancerJPRN-UMIN000028474Department of Internal Medicine, Division of Medical Oncology, Showa University School of Medicine.30
Recruiting
N/A
An exploratoly study to evaluate biomarkers in cell free DNA of "Sequential therapy from afatinib to osimertinib for EGFR mutant non small cell lung cancer: a multicenter prospective observational study (Gio Tag Japan)".non-small cell lung cancer(EGFR mutation positive)JPRN-UMIN000043235HANSHIN Oncology Group93
Completed
N/A
An exploratory study to evaluate biomarkers as predictive and /or prognostic factors of benefit from randomized phase ll study of mFOLFOX6+bevacizumab or mFOLFOX6+cetuximab in liver only metastasis from KRAS wild type colorectal cancerliver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol 2.0 edition) colorectal cancerJPRN-UMIN000010429EPS Corporation100